查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861934

生物製藥生產耗材檢測市場按產品類型、檢測類型、技術、應用和最終用戶分類 - 全球預測（2025-2032 年）

Biopharmaceuticals Manufacturing Consumables Testing Market by Product Type, Testing Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥生產耗材測試市場將成長至 15.524 億美元，複合年成長率為 12.12%。

關鍵市場統計數據
基準年 2024 6.2139億美元
預計年份：2025年 6.9693億美元
預測年份 2032 15.524億美元
複合年成長率 (%) 12.12%

了解耗材檢測在生物製藥生產中的基礎性作用，以及產品類型和檢測方法如何支援製程完整性。

隨著生物製藥生產的不斷發展，耗材檢測已成為品質保證、製程效率和法規遵循的關鍵環節。本執行摘要重點分析了從上游工程到下游整個生命週期中的耗材檢測實踐，著重闡述了用於保障產品安全和製程完整性的材料和方法。摘要首先檢視了層析法介質、過濾耗材、取樣組件、一次性使用袋和組件以及管路和接頭等產品類型，並展示了這些要素如何融入分析和放行前檢測體系。此外，概要也強調了微生物附著量、內毒素、pH值和無菌性檢測等檢測方法在生產控制策略和批次管理中發揮的關鍵作用。

要認知到，先進分析平台的普及、一次性產品的採用以及日益嚴格的監管正在迅速重新定義耗材測試和對供應商的期望。

由於技術應用、監管日益嚴格以及供應鏈重組，生物製藥耗材檢測領域正在經歷變革。分析平台的進步正在重塑製造商檢驗和監控耗材的方式。即時PCR和質譜分析能夠早期檢測污染物，而ELISA和流式細胞技術則繼續為關鍵的放行檢測流程提供支援。同時，一次性包裝袋、組件和整合管路系統的普及，使得可萃取物和萃取物評估、無菌保證以及相容性測試的重要性日益凸顯，迫使供應商在材料和滅菌方法方面進行創新。

評估近期美國關稅調整如何重塑耗材測試供應鏈的籌資策略、合格時間表和總成本考量。

美國近期關稅政策的變化為耗材測試組件的採購計畫和供應商策略帶來了新的變數。關稅調整影響進口層析法樹脂、過濾介質和專用一次性組件，進而影響最終到岸成本結構和前置作業時間。為此，許多製造商和供應商正在重新評估採購區域，修訂庫存政策，並加快近岸外包和雙重採購策略，以降低成本波動的風險。這些調整通常會導致更長的資格認證週期，因為替代材料和供應商需要進行適用性和性能檢驗。

了解產品類型、測試方法、分析技術、應用領域和最終用戶畫像如何共同決定測試優先事項和供應商選擇。

詳細的細分分析表明，產品類型、測試類型、技術、應用和最終用戶各自驅動耗材測試生態系統中不同的需求和策略性應對措施。在產品類型維度上，層析法介質、過濾耗材、採樣組件、一次性使用袋和組件以及管路和連接器構成了實驗室產品組合，這些產品組合必須經過相容性和性能檢驗。具體而言，層析法介質包括親和性和樹脂、離子交換樹脂、Protein A 樹脂和尺寸排阻介質，每種介質都有不同的清潔、再生和結合特性，這些特性會影響測試頻率和方法。過濾耗材包括濾芯過濾器、深度過濾器和薄膜過濾器，它們的選擇會影響無菌保證方法和顆粒監測通訊協定。一次性使用袋和組件包括生物反應器袋、混合袋和儲存袋，它們的材料選擇會影響可萃取物和可萃取物測試的範圍。

探討不同地區在製造業密度、法規結構和供應商生態系統的差異如何影響各地區的採購、驗證和測試策略。

區域趨勢對生物製造中耗材檢測的可用性、成本和監管要求產生了重大影響。在美洲，先進的製造地和一體化的供應鏈支援一次性系統和先進分析平台的快速普及，而監管機構對嚴格污染控制和產品可追溯性的重視正在塑造檢測要求。放眼東方，歐洲、中東和非洲地區（EMEA）呈現出多元化的格局，統一的法規結構與區域差異並存，迫使製造商在採用標準化檢測通訊協定的同時，還要應對特定區域的認證和進口流程。在亞太地區，不斷提升的本地製造能力以及對生物相似藥和契約製造的高度重視，正在推動對高通量檢測流程和區域供應商生態系統的投資，從而實現具有競爭力的前置作業時間和價格。

識別供應商和服務供應商之間的策略差異化因素，例如材料創新、自動化、可追溯性和區域製造韌性。

產業參與者涵蓋了從專業耗材和分析設備供應商到垂直整合供應商和第三方檢測實驗室等各類企業，從而形成了複雜的競爭格局。主要企業正投資於材料科學創新，以減少萃取物和浸出物；投資於無菌和微生物附著量測試自動化，以提高檢測效率；並投資於數位化可追溯性解決方案，以簡化文件記錄和供應商合格。耗材製造商和分析平台供應商之間的合作也不斷加強，透過提供預先認證組件和簡化的工作流程，減輕終端用戶的驗證負擔。同時，合約檢測機構也在拓展服務範圍，以支援分散式製造，包括整合樣品管理、快速週轉測試和法規報告。

實施品質和供應彈性策略，將供應商選擇、自動化分析、採購多元化和供應商協作開發結合。

產業領導者必須採取協調一致的策略，同時應對品質、供應韌性和成本壓力。首先，建立嚴格的供應商資格認證體系，包括多階段效能測試、原料來源驗證和合約服務水準預期，以減少對單一供應商的依賴。其次，優先投資分析自動化和資料整合，以縮短測試週期並改善決策。這包括將ELISA、PCR和質譜分析的工作流程與實驗室資訊管理系統相協調，從而實現快速趨勢分析。第三，透過對替代供應商和區域合作夥伴進行資格認證，促進採購多元化，並建立緊急庫存和靈活的合約結構，以應對關稅和物流中斷等情況。

我們採用混合方法研究途徑，結合技術文獻綜述、專家訪談、供應商文件和真實案例檢驗。

本執行摘要的調查方法整合了第一手和第二手資料，並經過同行檢驗，以確保其穩健性和相關性。首先，透過對技術文獻、法規指南和產品規格的系統性回顧，建立了對耗材和測試技術的基本理解，包括層析法介質、過濾類型、一次性組件和分析平台之間的功能差異。其次，透過與品管人員、採購專家和實驗室主任的訪談，獲得了關於供應商選擇標準、測試瓶頸以及應對關稅相關供應中斷的實際觀點。這些訪談輔以供應商產品文件和公開的法規文件，以對有關性能特徵和合檢驗方法的說法進行三角驗證。

摘要，要確保可靠且合規的生物製藥生產，策略上需要協調測試流程、供應商合格和分析能力。

總之，生物製藥生產中的耗材檢測是一項策略性職能，它直接影響產品品質、營運效率和監管合規性。不斷發展的技術、不斷變化的採購地域以及日益嚴格的監管，都要求製造商積極主動地進行供應商資質合格、投資分析能力建設並製定穩健的供應策略。透過專注於材料的適用性、方法的穩健性和供應商的透明度，企業可以縮短產品放行時間、減少批次不合格率並維護監管機構的信任。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合一次性感測器技術，用於即時監測關鍵生物過程程式參數
  • 在耗材性能檢驗中引入人工智慧驅動的預測品質分析
  • 新一代無菌檢測：利用快速微生物檢測平台
  • 採用具有高吸附能力的先進聚合物過濾器進行單株抗體純化過程
  • 標準化一次性生物製程組件的可萃取物和可浸出物測試通訊協定
  • 開發用於製程控制的可自訂一次性組件，該組件帶有在線連續壓力和電導率感測器
  • 為實現耗材測試工作流程的可追溯性和合規性，轉向雲端基礎的資料管理平台
  • 推出螢光的快速檢測一次性細胞培養基袋中微生物附著量的方法
  • 生物加工環境中耗材選擇與處置策略中生命週期永續性指標的重要性

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 生物製藥生產耗材檢測市場（依產品類型分類）

  • 層析法介質
    • 親和性和樹脂
    • 離子交換樹脂
    • 蛋白A樹脂
    • 尺寸排阻介質
  • 過濾耗材
    • 濾芯過濾器
    • 深度過濾器
    • 薄膜過濾器
  • 採樣組件
  • 一次性包裝袋和組件
    • 生物反應器袋
    • 喜憂參半
    • 收納袋
  • 管材和連接器

9. 生物製藥生產耗材檢測市場（依檢測類型分類）

  • 微生物附著量檢測
  • 內毒素試驗
  • pH測試
  • 無菌測試
    • 直接接種試驗
    • 膜過濾試驗

第10章 生物製藥生產耗材檢測市場（依技術分類）

  • ELISA
    • 競爭性ELISA
    • 間接ELISA
    • 夾心ELISA
  • 流式細胞技術
  • 質譜分析
  • 即時PCR

第11章 生物製藥生產耗材檢測市場（依應用領域分類）

  • 細胞培養監測
  • 蛋白質純化
    • 親和層析法
    • 離子交換層析法
    • 尺寸排阻層析法
  • 病毒清除

第12章 生物製藥生產耗材檢測市場（依最終用戶分類）

  • 學術研究機構
  • 生物製藥公司
    • 生物相似藥生產商
    • 大型製藥企業
    • 中型製藥公司
  • 契約製造組織
  • 受託研究機構

第13章 生物製藥生產耗材檢測市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生物製藥生產耗材檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國生物製藥生產耗材檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Sartorius AG
    • Corning Incorporated
    • Agilent Technologies Inc.
    • Lonza Group AG
    • PerkinElmer Inc.
    • Tecan Group Ltd
    • Repligen Corporation
Product Code: MRR-521BAA36EA7E

The Biopharmaceuticals Manufacturing Consumables Testing Market is projected to grow by USD 1,552.40 million at a CAGR of 12.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 621.39 million
Estimated Year [2025] USD 696.93 million
Forecast Year [2032] USD 1,552.40 million
CAGR (%) 12.12%

Understand the foundational role of consumables testing in biologics manufacturing and how product categories and testing modalities underpin process integrity

The evolution of biopharmaceutical manufacturing has placed consumables testing at the intersection of quality assurance, process efficiency, and regulatory compliance. This executive summary introduces a focused analysis of consumables testing practices across the upstream and downstream lifecycle, emphasizing materials and methods used to protect product safety and process integrity. Beginning with an exploration of product categories such as chromatography media, filtration consumables, sampling assemblies, single-use bags and assemblies, and tubing and connectors, the content frames how these elements integrate into analytical and release testing paradigms. It also highlights the critical role of testing modalities-bioburden, endotoxin, pH, and sterility assays-tied to manufacturing control strategies and batch disposition.

As manufacturing models shift toward single-use technologies, outsourced processing, and high-throughput biologics production, consumables testing increasingly determines the velocity of scale-up and the robustness of regulatory submissions. Therefore, this introduction establishes the foundation for deeper sections by clarifying the relationships between product families, testing types, and analytical technologies including ELISA variants, flow cytometry, mass spectrometry, and real-time PCR. The aim is to orient decision-makers to the primary levers that influence quality outcomes, supplier selection, and laboratory capability investments, enabling an immediate appreciation of downstream operational imperatives.

Recognize the convergence of advanced analytical platforms, single-use adoption, and regulatory tightening that is rapidly redefining consumables testing and supplier expectations

The biopharmaceutical consumables testing landscape is undergoing transformative shifts driven by technology adoption, regulatory tightening, and supply chain reconfiguration. Advances in analytical platforms are reshaping how manufacturers validate and monitor consumables, with real-time PCR and mass spectrometry enabling earlier detection of contaminants while ELISA and flow cytometry continue to support critical release testing workflows. At the same time, the move toward single-use bags, assemblies, and integrated tubing systems has increased the importance of extractables and leachables assessment, sterility assurance, and compatibility testing, prompting suppliers to innovate materials and sterilization approaches.

Concurrently, regulatory authorities globally are strengthening expectations for contamination control strategies and documentation rigor, elevating the importance of standardized testing protocols and traceable supply chains. Outsourcing models are evolving as contract manufacturing organizations and contract research organizations scale capabilities, creating demand for testing services optimized for throughput and regulatory defensibility. Taken together, these shifts require manufacturers to adopt a layered approach to risk management that couples advanced analytical techniques with robust vendor qualification, while investing in cross-functional teams capable of translating test data into process decisions.

Assess how recent United States tariff changes are reshaping sourcing strategies, qualification timelines, and total cost considerations for consumables testing supply chains

Recent tariff developments in the United States have introduced new variables into procurement planning and supplier strategy for consumables testing components. Tariff adjustments affect imported chromatography resins, filtration media, and specialized single-use assemblies, which in turn influence landed cost structures and lead time dynamics. In response, many manufacturers and suppliers are reassessing sourcing geographies, revisiting inventory policies, and accelerating nearshoring or dual-sourcing strategies to mitigate exposure to sudden cost shifts. These adjustments often cascade into longer qualification timelines as alternate materials and suppliers undergo compatibility and performance validation.

Importantly, tariff-driven cost pressures are not limited to direct purchasables; they extend to ancillary services, packaging, and logistics that support laboratory operations. Consequently, procurement teams are enhancing total-cost-of-ownership evaluations, prioritizing suppliers with resilient logistics networks and regional manufacturing footprints. Meanwhile, research and development groups are exploring material substitutions and process adjustments that reduce dependence on tariff-affected items without compromising critical quality attributes. Overall, the cumulative impact of tariffs has prompted a renewed emphasis on sourcing flexibility, supplier collaboration, and upfront risk assessment to preserve continuity of testing and release activities.

Unpack how product categories, testing modalities, analytical technologies, application areas, and end user profiles collectively determine testing priorities and supplier selection

A nuanced segmentation analysis reveals that product type, testing type, technology, application, and end user each drive distinct needs and strategic responses across the consumables testing ecosystem. Within the product type dimension, chromatography media, filtration consumables, sampling assemblies, single-use bags and assemblies, and tubing and connectors define portfolios that laboratories must validate for compatibility and performance. Chromatography media in particular spans affinity resins, ion exchange resins, protein A resins, and size exclusion media, each with different cleaning, regeneration, and binding characteristics that inform testing frequency and methods. Filtration consumables encompass cartridge filters, depth filters, and membrane filters, and their selection affects sterility assurance practices and particulate monitoring protocols. Single-use bags and assemblies include bioreactor bags, mixing bags, and storage bags, and their material choices influence extractables and leachables testing scope.

Testing type segmentation distinguishes between bioburden testing, endotoxin testing, pH testing, and sterility testing, recognizing that sterility testing itself often requires either direct inoculation or membrane filtration approaches that carry divergent sample handling and incubation requirements. Technology segmentation highlights how ELISA modalities, flow cytometry, mass spectrometry, and real-time PCR are used across testing workflows, noting that ELISA can be deployed as competitive, indirect, or sandwich formats depending on analyte and sensitivity needs. Application segmentation clarifies that cell culture monitoring, protein purification, and viral clearance each place different demands on consumable performance; protein purification techniques such as affinity chromatography, ion exchange chromatography, and size exclusion chromatography interact directly with media selection and downstream analytical checks. Finally, end users across academic and research institutes, biopharmaceutical companies, contract manufacturing organizations, and contract research organizations present varying procurement cycles, validation rigor, and volume needs, while biopharmaceutical companies themselves include biosimilar manufacturers, large pharma, and mid-size pharma with discrete regulatory risk appetites and supply chain priorities. Synthesizing these segmentation layers enables targeted strategies for supplier selection, testing protocol design, and laboratory capability investments that align with specific operational and regulatory contexts.

Explore how geographic differences in manufacturing density, regulatory frameworks, and supplier ecosystems shape procurement, validation, and testing strategies across regions

Regional dynamics exert a material influence on the availability, cost, and regulatory expectations surrounding consumables testing in biomanufacturing. In the Americas, advanced manufacturing hubs and integrated supply chains support rapid adoption of single-use systems and sophisticated analytical platforms, while regulatory agencies emphasize rigorous contamination control and product traceability that shape testing requirements. Moving eastward, Europe, the Middle East, and Africa present a heterogeneous landscape in which harmonized regulatory frameworks coexist with regional variability, prompting manufacturers to adopt standardized testing protocols while accommodating localized certification and import processes. In Asia-Pacific, rising local manufacturing capacity and a strong emphasis on biosimilars and contract manufacturing have driven investments in high-throughput testing workflows and regional supplier ecosystems that can offer competitive lead times and pricing.

Across these regions, differences in logistics infrastructure, customs procedures, and local supplier maturity lead manufacturers to tailor sourcing strategies that balance cost, lead time, and qualification burden. For global programs, leveraging regional distribution partners and aligning laboratory methods to meet cross-border regulatory expectations are essential strategies to ensure consistent quality outcomes. In short, geographic context matters not only for procurement but also for the design of validation studies, the selection of analytical technologies, and the prioritization of investments in local testing capacity.

Identify the strategic differentiators among suppliers and service providers including material innovation, automation, traceability, and regional manufacturing resilience

Industry participants range from specialized consumables and analytical equipment providers to vertically integrated suppliers and third-party testing laboratories, creating a complex competitive landscape. Leading companies are investing in material science innovations to reduce extractables and leachables, in automation of sterility and bioburden assays to increase throughput, and in digital traceability solutions to simplify documentation and supplier qualification. Partnerships between consumable manufacturers and analytical platform vendors are also emerging, aimed at delivering pre-qualified assemblies and simplified workflows that reduce the validation burden for end users. At the same time, contract testing organizations are expanding service offerings to include integrated sample management, rapid turnaround testing, and regulatory-compliant reporting to support decentralized manufacturing footprints.

As a result, differentiation is increasingly driven by a combination of technical support, regulatory know-how, and supply chain reliability rather than on price alone. Companies that can demonstrate robust quality systems, transparent material provenance, and flexible regional manufacturing capacity are better positioned to capture long-term relationships with biopharmaceutical developers and production sites. For procurement teams, evaluating potential partners requires assessing not only product performance but also the supplier's ability to collaborate on method transfer, participate in problem-solving during scale-up, and maintain continuity under geopolitical and logistical stressors.

Adopt an integrated quality and supply resilience playbook that combines vendor qualification, analytical automation, sourcing diversification, and collaborative supplier development

Industry leaders must adopt coordinated strategies that address quality, supply resilience, and cost pressures simultaneously. First, establish rigorous vendor qualification programs that incorporate multi-tiered performance testing, material provenance checks, and contractual service-level expectations to reduce reliance on single sources. Second, prioritize investments in analytical automation and data integration to shorten testing cycles and improve decision-making; this includes harmonizing ELISA, PCR, and mass spectrometry workflows with laboratory information management systems to enable rapid trend analysis. Third, pursue sourcing diversification by qualifying alternative suppliers and regional partners while developing contingency inventories and flexible contracting arrangements to buffer against tariff and logistics disruptions.

In parallel, organizations should accelerate collaborative initiatives with suppliers to co-develop pre-qualified assemblies and test-ready components that reduce validation time. Strengthening cross-functional teams that bring together procurement, quality, and R&D will improve responsiveness during scale-up and technology transfer. Finally, embed continuous improvement by monitoring performance metrics tied to testing throughput, supplier delivery consistency, and nonconformance rates, and use those metrics to prioritize where automation, supplier consolidation, or dual-sourcing deliver the greatest operational benefit. These combined actions will help leaders preserve product quality while managing the evolving economic and regulatory landscape.

Rely on a mixed-methods research approach combining technical literature review, expert interviews, supplier documentation, and validation through real-world case studies

The research methodology underpinning this executive summary integrates primary and secondary evidence with expert validation to ensure robustness and relevance. First, a structured review of technical literature, regulatory guidance, and product specifications established the foundational understanding of consumables and testing technologies, including the functional distinctions among chromatography media, filtration types, single-use assemblies, and analytical platforms. Second, targeted interviews with senior quality leaders, procurement specialists, and laboratory directors provided real-world perspectives on supplier selection criteria, testing bottlenecks, and responses to tariff-related supply disruptions. These conversations were supplemented by supplier product documentation and publicly available regulatory communications to triangulate claims about performance characteristics and compliance approaches.

Finally, synthesized findings were validated through cross-comparison of method transfer case studies and vendor qualification protocols to ensure practical applicability. Throughout the process, emphasis was placed on reproducibility of testing procedures, transparency of supplier quality systems, and the operational implications of regional supply chain constraints. This mixed-methods approach yields insights that are grounded in both technical detail and operational realities, providing a reliable basis for strategic decisions regarding consumables testing in biologics manufacturing.

Summarize the strategic imperative to align testing workflows, supplier qualification, and analytical capabilities to ensure reliable and compliant biologics production

In conclusion, consumables testing in biopharmaceutical manufacturing is a strategic function that influences product quality, operational efficiency, and regulatory success. The interplay of evolving technologies, shifting sourcing geographies, and heightened regulatory scrutiny requires manufacturers to be proactive in qualifying suppliers, investing in analytical capability, and designing resilient supply strategies. By focusing on material compatibility, method robustness, and supplier transparency, organizations can reduce time-to-release, limit batch failures, and maintain regulatory confidence.

Moving forward, companies that integrate advanced analytical platforms with automated data management and that cultivate collaborative supplier relationships will be best positioned to manage cost pressures and mitigate tariff-related risks. Ultimately, the decisions made today about testing workflows, procurement practices, and regional footprint will determine an organization's ability to scale biologics production reliably and compliantly across diverse markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of single-use sensor technologies for real-time monitoring of critical bioprocess parameters
  • 5.2. Adoption of AI-driven predictive quality analytics in consumable performance validation
  • 5.3. Implementation of next-generation sterility testing using rapid microbial detection platforms
  • 5.4. Use of advanced polymeric filters with high binding capacities for monoclonal antibody purification processes
  • 5.5. Standardization of extractables and leachables testing protocols for single-use bioprocess assemblies
  • 5.6. Development of customizable single-use assemblies with inline pressure and conductivity sensors for process control
  • 5.7. Shift towards cloud-based data management platforms for traceability and compliance in consumable testing workflows
  • 5.8. Incorporation of fluorescence-based assays for rapid detection of bioburden in single-use cell culture media bags
  • 5.9. Emphasis on lifecycle sustainability metrics in consumable selection and disposal strategies within bioprocess environments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceuticals Manufacturing Consumables Testing Market, by Product Type

  • 8.1. Chromatography Media
    • 8.1.1. Affinity Resins
    • 8.1.2. Ion Exchange Resins
    • 8.1.3. Protein A Resins
    • 8.1.4. Size Exclusion Media
  • 8.2. Filtration Consumables
    • 8.2.1. Cartridge Filters
    • 8.2.2. Depth Filters
    • 8.2.3. Membrane Filters
  • 8.3. Sampling Assemblies
  • 8.4. Single-Use Bags And Assemblies
    • 8.4.1. Bioreactor Bags
    • 8.4.2. Mixing Bags
    • 8.4.3. Storage Bags
  • 8.5. Tubing And Connectors

9. Biopharmaceuticals Manufacturing Consumables Testing Market, by Testing Type

  • 9.1. Bioburden Testing
  • 9.2. Endotoxin Testing
  • 9.3. pH Testing
  • 9.4. Sterility Testing
    • 9.4.1. Direct Inoculation Test
    • 9.4.2. Membrane Filtration Test

10. Biopharmaceuticals Manufacturing Consumables Testing Market, by Technology

  • 10.1. ELISA
    • 10.1.1. Competitive ELISA
    • 10.1.2. Indirect ELISA
    • 10.1.3. Sandwich ELISA
  • 10.2. Flow Cytometry
  • 10.3. Mass Spectrometry
  • 10.4. Real-Time PCR

11. Biopharmaceuticals Manufacturing Consumables Testing Market, by Application

  • 11.1. Cell Culture Monitoring
  • 11.2. Protein Purification
    • 11.2.1. Affinity Chromatography
    • 11.2.2. Ion Exchange Chromatography
    • 11.2.3. Size Exclusion Chromatography
  • 11.3. Viral Clearance

12. Biopharmaceuticals Manufacturing Consumables Testing Market, by End User

  • 12.1. Academic And Research Institutes
  • 12.2. Biopharmaceutical Companies
    • 12.2.1. Biosimilar Manufacturers
    • 12.2.2. Large Pharma
    • 12.2.3. Mid-Size Pharma
  • 12.3. Contract Manufacturing Organizations
  • 12.4. Contract Research Organizations

13. Biopharmaceuticals Manufacturing Consumables Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceuticals Manufacturing Consumables Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceuticals Manufacturing Consumables Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Sartorius AG
    • 16.3.5. Corning Incorporated
    • 16.3.6. Agilent Technologies Inc.
    • 16.3.7. Lonza Group AG
    • 16.3.8. PerkinElmer Inc.
    • 16.3.9. Tecan Group Ltd
    • 16.3.10. Repligen Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CHROMATOGRAPHY MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY RESINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE RESINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN A RESINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FILTRATION CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CARTRIDGE FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DEPTH FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SAMPLING ASSEMBLIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SINGLE-USE BAGS AND ASSEMBLIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOREACTOR BAGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MIXING BAGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STORAGE BAGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TUBING AND CONNECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY BIOBURDEN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ENDOTOXIN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PH TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY STERILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY DIRECT INOCULATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MEMBRANE FILTRATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY CELL CULTURE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY VIRAL CLEARANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOPHARMACEUTICALS MANUFACTURING CONSUMABLES TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018